53.13
53.13 (0.17%)
As of Mar 06, 2024
Related Stories
- California Resources Corp Reports annual revenue of $2.8 billion
- Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides ...
- BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results
- Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
- Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer